Navigation Links
Omeros Reports Additional Positive Results from OMS824 Program
Date:9/12/2013

evel is scheduled to be evaluated in the ongoing PET trial and is expected to demonstrate substantially higher target engagement. The Phase 1 clinical trial results predict that OMS824, at well-tolerated doses, will effectively inhibit PDE10 and support continuing development for the treatment of Huntington's disease, schizophrenia and other central nervous system disorders.

"These findings are unprecedented based on our knowledge of the work to date in the area of PDE10 inhibition and could result in a significant competitive advantage across a range of CNS indications," stated Gregory A. Demopulos, M.D., chairman and chief executive officer of Omeros. "With this further confirmation of the unique pharmacology of our PDE10 inhibitor, Omeros is well positioned to initiate Phase 2 programs in schizophrenia and Huntington's disease before year-end."

About Omeros' PDE10 Program
PDE10 is an enzyme that is expressed in areas of the brain linked to diseases that affect cognition and psychomotor functions, including Huntington's disease and schizophrenia. Huntington's disease is a hereditary neurodegenerative disorder that leads to movement, cognition, and behavioral abnormalities and premature death. Schizophrenia is a group of severe brain disorders characterized by an abnormal interpretation of reality, which can manifest as delusions, hallucinations, and/or disordered thinking and behavior. Cognitive dysfunction is responsible for substantial disability in both of these diseases and is not meaningfully improved by current medications. Omeros' proprietary compound OMS824 inhibits PDE10 and is being developed for the treatment of cognitive disorders. In addition to potential benefits on cognition, OMS824 could also improve the motor and psychiatric abnormalities in Huntington's disease as well as the positive (e.g., hallucinations) and negative (e.g., flat affect) symptoms of schizophrenia.

About Omeros Corporation'/>"/>

SOURCE Omeros Corporation
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Omeros Submits OMS302 Marketing Authorization Application to European Medicines Agency
2. Omeros to Present at the Stifel Healthcare Conference 2013
3. Michael A. Jacobsen Joining Omeros as Vice President, Finance and Chief Accounting Officer
4. Omeros Corporation Reports Second Quarter 2013 Financial Results
5. Omeros to Present at the Wedbush 2013 Life Sciences Management Access Conference
6. Omeros Submits New Drug Application to U.S. FDA for OMS302
7. Omeros Reports Positive Results from OMS824 Positron Emission Tomography Clinical Trial
8. Omeros Files Clinical Trial Application for Lead Antibody in MASP-2 Program
9. Omeros Corporation Reports First Quarter 2013 Financial Results
10. Omeros Announces $16.2 Million Registered Direct Offering of Common Stock
11. Omeros Ophthalmology Product OMS302 Granted Eligibility for European Centralized Review
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/18/2014)... Mass. , Nov. 18, 2014 Respiratory ... of the leading medical device and services providers in ... exclusive partner for Respiratory Motion,s innovative respiratory depression monitor, ... Motion and IMI are working together to connect the ... has a long history of bringing innovative medical devices ...
(Date:11/18/2014)... , Nov. 18, 2014  TransCelerate ... its most recent manuscript on Risk-Based Monitoring ... a Quality Control Measure in Clinical Trials ... Therapeutic Innovation & Regulatory Science  (TIRS) journal. ... collaboration with Medidata, the manuscript examines the ...
(Date:11/18/2014)... FT LAUDERDALE, Fla. , November 18, 2014 ... ), a leading solution provider of access control ... the company has joined the Green Rush Alliance ... solutions to  customers and businesses in the Cannabis ... products and services to medical marijuana dispensaries, retailers ...
Breaking Medicine Technology:Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 2Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 3Prominent Japanese Med Device Provider to be Respiratory Motion's Exclusive Partner for World's #2 Medical Market 4TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 2TransCelerate BioPharma Inc. Publishes Recommendation on Use of Source Data Verification in Risk-Based Monitoring, Releases Third Update on Initiative Progress 3Profile Solutions, Inc Joins the Green Rush Alliance 2Profile Solutions, Inc Joins the Green Rush Alliance 3
... 22, 2011 /PRNewswire-Asia/ -- China Health Resource, Inc. (OTCBB: ... (TCM) products, announced robust record breaking quarterly earnings for ... and $1.8 million in net income, a 219% increase ... the third quarter of 2010. This translates to earnings ...
... HILL, N.C., Nov. 21, 2011  In today,s payer-driven market, ... of a new pharmaceutical product. However, sustaining commercial success ... processes that will increase market share after the product ... of practices to manage the challenges of the pull-through ...
Cached Medicine Technology:China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 2China Health Resource Announces Record Breaking 3rd Quarter 2011 Financial Results 3Managed Care Pull-Through Programs Target Physicians, Boost Market Share 2
(Date:11/18/2014)... November 18, 2014 Medicationdiscountcard.com's ... insights, adding to the company's reputation for helping ... the blog has to offer at http://blog.medicationdiscountcard.com/ ... the information concerning the Affordable Care Act and ... to inform the public about a variety of ...
(Date:11/18/2014)... Dennis Thompson HealthDay Reporter ... experimental antibody drug could prove effective at lowering LDL ... with cholesterol-lowering statin medications. That,s the conclusion of ... Association annual meeting in Chicago. The drug, alirocumab, ... widely used alternative to statins, Zetia, said lead researcher ...
(Date:11/18/2014)... News) -- Women who started smoking at a young ... menstrual pain, a new study suggests. About 29 ... has been suspected as a risk factor for severe ... of the new study said. The researchers analyzed ... study of women,s health in Australia. About 14 percent ...
(Date:11/18/2014)... 2014 Global Partnership for ... telehealth platform to bring quality healthcare to populations ... GPT created Global Partnership for TeleHealth Missions (GPTM), ... telehealth network. GPTM focuses specifically on medical ... disaster relief organizations. , Michael D’Ambrosio, ...
(Date:11/18/2014)... Beach, Virginia (PRWEB) November 18, 2014 ... experience frustrating situations with print devices like unforeseen error ... when they don't have time to find another printer ... the issue. The IT department is likely tied up ... familiar? , That’s where Electronic Systems, ...
Breaking Medicine News(10 mins):Health News:Medicationdiscountcard.com Building Virtual Library of Resources to Help Consumers Navigate Healthcare Landscape 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 2Health News:Experimental Cholesterol-Lowering Drug Effective, Study Reports 3Health News:Study Ties Teen Smoking to Risk of Severe Menstrual Cramps 2Health News:Global Partnership for TeleHealth (GPT) is Focused on Using the telehealth Platform to Bring Quality Healthcare to Populations in Need Worldwide 2Health News:Electronic Systems, providing Managed Print Services (MPS) in Virginia & Outer Banks North Carolina 2
... CareMedic Systems ( http://www.caremedic.com ... patient financial data, has entered into an OEM agreement with ... ), for its Cincom Knowledge Master(R) software to ... , , Registration-based data-quality issues represent a significant source ...
... Researchers from the Kennedy Krieger Institute and Johns Hopkins ... new insights into the neurological basis of autism. Their ... , examined patterns of movement as children with autism ... tool. The findings suggest that children with autism appear ...
... Calif., July 6 Quest International, Inc. announced it was ... Global Supplier of the Year Award. This is the ... the award, receiving honors in 2006 as well. , ... Annual Supplier Conference. Quest was selected for their recognition ...
... could include microscopic beads that create "designer" immune cells ... of Georgia researchers say. "It,s absolutely natural," says ... for Molecular Chaperone/Radiobiology and Cancer Virology, who has used ... The degradable microparticles deliver the most powerful known form ...
... General Dynamics Information Technology, a business unit of General ... $9.2 million dollar, three-year contract to support the U.S. Army ... , General Dynamics will support the Army MEDCOM Lean ... consulting services to internal organizations for MEDCOM,s Director of Strategy ...
... Dick, Senior Scientist at the Ontario Cancer Institute, the ... team that has developed the first leukemia therapy that ... stem cells that drive acute myeloid leukemia (AML), which ... Dr. Richard Lock is leading the clinical trial ...
Cached Medicine News:Health News:CareMedic and Cincom Sign OEM Technology Partnership for Healthcare Solution 2Health News:New study pinpoints difference in the way children with autism learn new behaviors 2Health News:New study pinpoints difference in the way children with autism learn new behaviors 3Health News:Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 2Health News:Quest International Repeats Win as Siemens Healthcare Best Global Supplier of the Year 3Health News:Microscopic 'beads' could help create 'designer' immune cells that ignore transplanted organs 2Health News:General Dynamics Awarded $9 Million Contract for U.S. Army Medical Command Lean Six Sigma Support 2Health News:Toronto researcher's discovery points to a new treatment avenue for acute myeloid leukemia 2
... Mosaic, the third generation tissue valve ... stented tissue valve available. The Mosaic valve ... experience and is an excellent choice for ... replacement with a tissue valve. For more ...
... bioprosthesis from Medtronic has more ... clinical experience. Worldwide clinical studies ... structural valve deterioration with Hancock® ... is substantially better than results ...
... The Hancock® II bioprosthesis ... 15 years of proven clinical ... that the freedom from structural ... aortic and mitral bioprostheses is ...
Attain Venogram Balloon Catheter....
Medicine Products: